Photo

Mr. Jacob Harel

Chairman of the Board
Mr. Harel has more than 30 years’ experience in sales, marketing, operation and business development in the global pharmaceutical industry. He demonstrated ability to establish strategic directions, to operate teams in international environments (Europe, Asia, U.S., Latin America, and Middle East) and to accomplish challenging business objectives. Mr. Harel is the founder and president of “The Harel Group”, a business development advisory firm supporting international transactions in the global pharmaceutical industry. Prior to founding “The Harel Group”, Mr. Harel spent more than 27 years at Merck & Co., Inc. in leadership roles in sales, marketing and business development. Most recently, as Executive Director and Head of Corporate Business Development, Mr. Harel led the negotiation and execution of key enterprise transactions, including joint ventures, divestitures, commercial collaborations, licensing and distribution agreements. Mr. Harel holds a Bachelor of Science degree in Economics, from Haifa University, and an MBA in marketing, from Tel Aviv University, Israel.
Chairman of the Board
  • Member of the Audit Committee

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >